Active ingredientMetixene Hydrochloride MonohydrateCat. No. P-M105-001CAS 7081-40-5Family · Pharmaceutical analytical standards
Metixene
An anticholinergic (antimuscarinic) drug with a thioxanthene structure, prepared in the late 1950s and patented in 1959: it is used for the symptoms of parkinsonism. This family brings together the active ingredient and pharmacopoeial impurities.
Did you know?Studies in animal models showed that it triggers incomplete autophagy in cancer cells: in mice it killed metastatic breast cancer cells and extended survival in the presence of brain metastases.
Go to the active ingredient →Active ingredientMetixene Hydrochloride MonohydrateCat. No. P-M105-001CAS 7081-40-5
Pharmacopoeial impurityMetixene Hydrochloride EP Impurity ACat. No. P-M105-002CAS 261-31-4
Pharmacopoeial impurityMetixene Hydrochloride EP Impurity BCat. No. P-M105-003CAS 492-22-8No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substanceMetixene hydrochloride CRSEDQM code M1808000Family MetixeneReference substanceThioxanthene CRSEDQM code T1305100Family MetixeneReference substanceThioxanthone CRSEDQM code T1305000Family MetixeneNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.